Wellspring’s parent company, Mawdsleys, has recently acquired Luto Research to build upon its existing expertise in clinical trial services. Luto specialises in developing, enhancing and testing communications to patients and healthcare professionals, and will naturally complement Mawdsleys’ clinical trials division, Wellspring Clinical
Commenting on the acquisitions, Ian Brownlee, chief executive of Mawdsleys said: “We believe that Luto’s pioneering work in testing and refining patient and healthcare professional communications will have immediate synergies with other group companies such as Wellspring. We are particularly keen to apply the methodology resulting from Luto’s research into the area of clinical trials patient information and informed consent, which we believe will bring real benefits to clients.”
The acquisition serves to strengthen the capabilities of Wellspring, which specialises in providing worldwide support in the clinical trials arena.